TerminatedPhase 1

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Stopped: Financial reasons

United States, Australia1 participantsStarted 2024-09-06

Plain-language summary

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).

Who can participate

Age range18 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. LBCL
✓. FL Grade 3b
✓. MCL
✓. must have achieved either a CR or partial response as a best response and maintained the response for ≥ 3 months after receiving CD19-directed treatment, and
✓. must still have CD19+ disease as determined by a local laboratory.

What they're measuring

Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)

Timeframe: Day 1 through 90 days after the last dose of study drug

Incidence and Severity of Adverse Events of Special Interest (AESIs)

Timeframe: Day 1 through 90 days after the last dose of study drug

Number of Participants With Clinically Significant Changes in Laboratory Parameters

Timeframe: Day 1 through 90 days after the last dose of study drug

Incidence of Dose-limiting Toxicities (DLTs)

Timeframe: Day 1 through Day 28 of first dose

Maximum Tolerated dose (MTD)

Timeframe: Day 1 through Day 28 of first dose

Recommended Phase 2 Dose (RP2D)

Timeframe: Day 1 through Day 28 of first dose

Trial details

NCT IDNCT06256484

SponsorAtara Biotherapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-03-03

View on ClinicalTrials.gov More Relapsed/Refractory B-cell Non-Hodgkin Lymphoma trials